222 related articles for article (PubMed ID: 33632668)
1. A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Ribrag V; Lee ST; Rizzieri D; Dyer MJS; Fayad L; Kurzrock R; Andritsos L; Bouabdallah R; Hayat A; Bacon L; Jiang Y; Miah K; Delafont B; Hamid O; Anyanwu S; Martinez P; Hess B
Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):309-317.e3. PubMed ID: 33632668
[TBL] [Abstract][Full Text] [Related]
2. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
[TBL] [Abstract][Full Text] [Related]
3. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study.
Nishina T; Fujita T; Yoshizuka N; Sugibayashi K; Murayama K; Kuboki Y
BMJ Open; 2022 Oct; 12(10):e055718. PubMed ID: 36270753
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J
JAMA Oncol; 2019 Feb; 5(2):195-203. PubMed ID: 30383184
[TBL] [Abstract][Full Text] [Related]
6. Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.
Garon EB; Spira AI; Goldberg SB; Chaft JE; Papadimitrakopoulou V; Cascone T; Antonia SJ; Brahmer JR; Camidge DR; Powderly JD; Wozniak AJ; Felip E; Wu S; Ascierto ML; Elgeioushi N; Awad MM
J Thorac Oncol; 2023 Aug; 18(8):1094-1102. PubMed ID: 37146752
[TBL] [Abstract][Full Text] [Related]
7. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.
Chen EX; Jonker DJ; Loree JM; Kennecke HF; Berry SR; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski SL; Wei AC; Magoski NM; Tu D; O'Callaghan CJ
JAMA Oncol; 2020 Jun; 6(6):831-838. PubMed ID: 32379280
[TBL] [Abstract][Full Text] [Related]
8. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
9. Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.
Herrera AF; Goy A; Mehta A; Ramchandren R; Pagel JM; Svoboda J; Guan S; Hill JS; Kwei K; Liu EA; Phillips T
Am J Hematol; 2020 Jan; 95(1):18-27. PubMed ID: 31621094
[TBL] [Abstract][Full Text] [Related]
10. Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment.
Roschewski M; Patel MR; Reagan PM; Saba NS; Collins GP; Arkenau HT; de Vos S; Nuttall B; Acar M; Burke K; White RD; Udriste M; Sharma S; Dougherty B; Stetson D; Jenkins D; Mortlock A; Forcina A; Munugalavadla V; Flinn I
Clin Cancer Res; 2023 Sep; 29(17):3301-3312. PubMed ID: 37364001
[TBL] [Abstract][Full Text] [Related]
11. Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.
Pakkala S; Higgins K; Chen Z; Sica G; Steuer C; Zhang C; Zhang G; Wang S; Hossain MS; Nazha B; Beardslee T; Khuri FR; Curran W; Lonial S; Waller EK; Ramalingam S; Owonikoko TK
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428583
[TBL] [Abstract][Full Text] [Related]
12. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
Ferris RL; Haddad R; Even C; Tahara M; Dvorkin M; Ciuleanu TE; Clement PM; Mesia R; Kutukova S; Zholudeva L; Daste A; Caballero-Daroqui J; Keam B; Vynnychenko I; Lafond C; Shetty J; Mann H; Fan J; Wildsmith S; Morsli N; Fayette J; Licitra L
Ann Oncol; 2020 Jul; 31(7):942-950. PubMed ID: 32294530
[TBL] [Abstract][Full Text] [Related]
13. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
Reilley MJ; McCoon P; Cook C; Lyne P; Kurzrock R; Kim Y; Woessner R; Younes A; Nemunaitis J; Fowler N; Curran M; Liu Q; Zhou T; Schmidt J; Jo M; Lee SJ; Yamashita M; Hughes SG; Fayad L; Piha-Paul S; Nadella MVP; Xiao X; Hsu J; Revenko A; Monia BP; MacLeod AR; Hong DS
J Immunother Cancer; 2018 Nov; 6(1):119. PubMed ID: 30446007
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07.
Kim M; Keam B; Ock CY; Kim SH; Kim YJ; Lim SM; Kim JS; Kim TM; Hong SH; Ahn MS; Shin SH; Kang EJ; Kim DW; Im SW; Kim JI; Lee JS; Kim JH; Heo DS
Thorac Cancer; 2020 Dec; 11(12):3482-3489. PubMed ID: 33026712
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
Leighl NB; Redman MW; Rizvi N; Hirsch FR; Mack PC; Schwartz LH; Wade JL; Irvin WJ; Reddy SC; Crawford J; Bradley JD; Stinchcombe TE; Ramalingam SS; Miao J; Minichiello K; Herbst RS; Papadimitrakopoulou VA; Kelly K; Gandara DR
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34429332
[TBL] [Abstract][Full Text] [Related]
16. Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial.
Boilève A; Hilmi M; Gougis P; Cohen R; Rousseau B; Blanc JF; Ben Abdelghani M; Castanié H; Dahan L; Tougeron D; Metges JP; Tournigand C; Garcia-Larnicol ML; Vernerey D; Turpin A; Neuzillet C
Eur J Cancer; 2021 Jan; 143():55-63. PubMed ID: 33279854
[TBL] [Abstract][Full Text] [Related]
17. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
Kelley RK; Sangro B; Harris W; Ikeda M; Okusaka T; Kang YK; Qin S; Tai DW; Lim HY; Yau T; Yong WP; Cheng AL; Gasbarrini A; Damian S; Bruix J; Borad M; Bendell J; Kim TY; Standifer N; He P; Makowsky M; Negro A; Kudo M; Abou-Alfa GK
J Clin Oncol; 2021 Sep; 39(27):2991-3001. PubMed ID: 34292792
[TBL] [Abstract][Full Text] [Related]
18. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
[TBL] [Abstract][Full Text] [Related]
19. Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer.
Doki Y; Ueno M; Hsu CH; Oh DY; Park K; Yamamoto N; Ioka T; Hara H; Hayama M; Nii M; Komuro K; Sugimoto M; Tahara M
Cancer Med; 2022 Jul; 11(13):2550-2560. PubMed ID: 35611499
[TBL] [Abstract][Full Text] [Related]
20. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment.
Subudhi SK; Siddiqui BA; Aparicio AM; Yadav SS; Basu S; Chen H; Jindal S; Tidwell RSS; Varma A; Logothetis CJ; Allison JP; Corn PG; Sharma P
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
